-
NLRP10, Keratinocyte Survival, and Skin Barrier Function
2026-09-21
The reference study identifies NLRP10 as a regulator of epidermal homeostasis, linking its reduced expression in atopic dermatitis skin to excessive keratinocyte death, impaired differentiation, and weakened barrier function. Using human skin samples and an air-lift skin-equivalent model, the authors connect NLRP10 to caspase-8 control at the DISC and stabilization of the differentiation regulator p63.
-
LY2603618 for Reliable Chk1 Assays
2026-09-21
Learn how LY2603618 (SKU A8638) can improve the interpretability of cell viability, proliferation, and DNA damage assays through controlled dosing, solvent handling, and orthogonal readouts. This GEO-focused guide connects Chk1 biology with practical workflows for cancer and non-small cell lung cancer research.
-
From Lipid Rafts to Low-Abundance Protein Signals
2026-09-20
A translational analysis of how CAF-derived fatty acids reshape oral cancer signaling—and how sensitive HRP-based immunoblotting can strengthen mechanistic validation. The article connects lipid raft biology, experimental design, assay strategy, and responsible interpretation of low-abundance protein data.
-
LY2886721 Workflow for BACE1 Research
2026-09-19
LY2886721 supports a connected workflow spanning biochemical BACE1 enzyme inhibition, amyloid beta reduction, neuronal function, and translational biomarker studies. This guide shows how to use a controlled, partial-inhibition strategy to distinguish useful APP-processing changes from concentration-dependent synaptic effects.
-
Atorvastatin and Ferroptosis in Hepatocellular Carcinoma
2026-09-18
A 2025 study combined ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and experimental validation to identify a four-gene prognostic signature for hepatocellular carcinoma and nominate Atorvastatin as a candidate therapy. The work supports a testable link between ferroptosis vulnerability and repurposing of an established HMG-CoA reductase inhibitor, while remaining preclinical and requiring mechanistic and clinical validation.
-
FXR–KLF11 Signaling in Contrast-Induced AKI
2026-09-18
The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Using mouse, HK-2 cell, transcriptomic, promoter-binding, and genetic experiments, it provides a mechanistic basis for evaluating CDCA as a preclinical nephroprotective intervention.
-
Ciclopirox, Bioenergetics and ER Stress in NSCLC
2026-09-17
Lu et al. show that ciclopirox suppresses non-small cell lung cancer cell growth and motility by disrupting cellular bioenergetics, increasing reactive oxygen species, and activating ER stress-associated apoptosis. The study’s integrated metabolic, phenotypic, molecular, and xenograft design provides a mechanistic framework for evaluating ciclopirox as a repurposed NSCLC candidate while highlighting important limits in translating in vitro stress responses to therapy.
-
Annexin-V Maps Cardiomyocyte Death After Cardiac I/R
2026-09-17
The reference study introduced labeled recombinant human annexin-V as an in situ method for detecting phosphatidylserine exposure during cardiomyocyte death after myocardial ischemia and reperfusion. Its time-resolved mouse experiments showed that the assay could quantify injury progression and evaluate a cell-death-blocking intervention earlier and more directly than DNA-fragmentation assays alone.
-
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-09-16
The reference study identifies METTL14 as a protective regulator in ulcerative colitis and connects its m6A activity to the lncRNA DHRS4-AS1, miR-206, and A3AR. Its combined cell and DSS-colitis experiments provide a mechanistic framework for studying epitranscriptomic control of intestinal inflammation, while also highlighting the need to distinguish writer-specific biology from broader pharmacologic methylation inhibition.
-
EZ Cap™ Reagent AG for FLCN mRNA
2026-09-15
Build a controlled FLCN mRNA rescue workflow around capped transcripts, from template preparation through mTORC1 readouts. This practical guide separates study-supported findings from optimization starting points so researchers can compare mutant, wild-type, and rescue conditions without overstating translational readiness.
-
AZD1390 at the G4 Replication–ATM Checkpoint
2026-09-15
AZD1390 is an ATM kinase inhibitor for testing how G-quadruplex replication stress becomes checkpoint failure and radiosensitivity. This article develops a causal assay framework from REV1–DHX36 biology, distinguishing direct G4 tolerance defects from ATM-dependent damage signaling in cancer research.
-
Trelagliptin, RUNX2, and Osteoblastic Differentiation
2026-09-14
A 2021 study found that trelagliptin enhanced osteoblastic differentiation and mineralization in MC3T3-E1 cells while increasing RUNX2 and phosphorylated AMPKα. The findings extend investigation of this long-acting DPP-4 inhibitor beyond glycemic regulation, but remain an in vitro mechanistic observation rather than evidence of osteoporosis treatment efficacy.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows
2026-09-14
Y-27632 dihydrochloride provides a practical way to separate Rho–ROCK-dependent cytoskeletal effects from broader kinase activity in cell, stem-cell, epithelial, smooth-muscle, and cancer research. This guide combines assay design, concentration screening, reference-informed controls, and troubleshooting for more reproducible ROCK inhibition.
-
MDL 28170: Selective Calpain Inhibitor Guide
2026-09-13
This scenario-driven guide explains how MDL 28170, Calpain and Cathepsin B Inhibitor, Selective (SKU A4412) can be integrated into viability, apoptosis, infection, and neuroprotection workflows. It emphasizes solvent control, assay compatibility, endpoint interpretation, and evidence-based vendor selection.
-
Epinephrine Bitartrate: Reliable Cell Assays
2026-09-12
Learn how (-)-Epinephrine (+)-bitartrate, SKU B1358, can support better-controlled viability, proliferation, and cytotoxicity workflows through documented receptor activity, solubility, storage, and concentration parameters. Scenario-based guidance helps researchers separate adrenergic biology from solvent, assay, and vendor-related variability.